These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

327 related items for PubMed ID: 28819835

  • 1. Efficacy and Safety of Linagliptin in 2681 Asian Patients Stratified by Age, Obesity, and Renal Function: A Pooled Analysis of Randomized Clinical Trials.
    Ning G, Bandgar T, Hehnke U, Lee J, Chan JCN.
    Adv Ther; 2017 Sep; 34(9):2150-2162. PubMed ID: 28819835
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of linagliptin in Asian patients with type 2 diabetes mellitus inadequately controlled by metformin: A multinational 24-week, randomized clinical trial.
    Wang W, Yang J, Yang G, Gong Y, Patel S, Zhang C, Izumoto T, Ning G.
    J Diabetes; 2016 Mar; 8(2):229-37. PubMed ID: 25753488
    [Abstract] [Full Text] [Related]

  • 3. Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia.
    Ross SA, Caballero AE, Del Prato S, Gallwitz B, Lewis-D'Agostino D, Bailes Z, Thiemann S, Patel S, Woerle HJ, von Eynatten M.
    Postgrad Med; 2016 Nov; 128(8):747-754. PubMed ID: 27684308
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.
    Lajara R, Aguilar R, Hehnke U, Woerle HJ, von Eynatten M.
    Clin Ther; 2014 Nov 01; 36(11):1595-605. PubMed ID: 25236917
    [Abstract] [Full Text] [Related]

  • 5. Long-Term Efficacy and Safety of Linagliptin in a Japanese Population with Type 2 Diabetes Aged ≥ 60 Years Treated with Basal Insulin: A Randomised Trial.
    Araki E, Unno Y, Tanaka Y, Sakamoto W, Miyamoto Y.
    Adv Ther; 2019 Oct 01; 36(10):2697-2711. PubMed ID: 31482511
    [Abstract] [Full Text] [Related]

  • 6. [The efficacy and safety of linagliptin in elderly patients with type 2 diabetes: a pooled analysis of eight placebo-controlled clinical trials].
    Guo XH, Feng ZK, Xu LH.
    Zhonghua Nei Ke Za Zhi; 2017 Aug 01; 56(8):588-594. PubMed ID: 28789492
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial.
    Laffel LM, Danne T, Klingensmith GJ, Tamborlane WV, Willi S, Zeitler P, Neubacher D, Marquard J, DINAMO Study Group.
    Lancet Diabetes Endocrinol; 2023 Mar 01; 11(3):169-181. PubMed ID: 36738751
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of linagliptin to improve glucose control in older people with type 2 diabetes on stable insulin therapy: A randomized trial.
    Ledesma G, Umpierrez GE, Morley JE, Lewis-D'Agostino D, Keller A, Meinicke T, van der Walt S, von Eynatten M.
    Diabetes Obes Metab; 2019 Nov 01; 21(11):2465-2473. PubMed ID: 31297968
    [Abstract] [Full Text] [Related]

  • 9. Comparative efficacy and safety of gemigliptin versus linagliptin in type 2 diabetes patients with renal impairment: A 40-week extension of the GUARD randomized study.
    Han SY, Yoon SA, Han BG, Kim SG, Jo YI, Jeong KH, Oh KH, Park HC, Park SH, Kang SW, Na KR, Kang SW, Kim NH, Jang Y, Kim B, Shin S, Cha DR.
    Diabetes Obes Metab; 2018 Feb 01; 20(2):292-300. PubMed ID: 28719008
    [Abstract] [Full Text] [Related]

  • 10. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.
    Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK, CARMELINA® investigators.
    Cardiovasc Diabetol; 2018 Mar 14; 17(1):39. PubMed ID: 29540217
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of linagliptin/metformin single-pill combination as initial therapy in drug-naïve Asian patients with type 2 diabetes.
    Mu Y, Pan C, Fan B, Hehnke U, Zhang X, Zhang X, Wang X, Liu J, Zhang Y, Du J, Ma J, Gong Y.
    Diabetes Res Clin Pract; 2017 Feb 14; 124():48-56. PubMed ID: 28088030
    [Abstract] [Full Text] [Related]

  • 12. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH, Patel S, Harper R, Toorawa R, Thiemann S, von Eynatten M, Woerle HJ.
    Diabetes Obes Metab; 2012 Dec 14; 14(12):1145-54. PubMed ID: 22974280
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of linagliptin in subjects with type 2 diabetes mellitus and poor glycemic control: pooled analysis of data from three placebo-controlled phase III trials.
    Del Prato S, Taskinen MR, Owens DR, von Eynatten M, Emser A, Gong Y, Chiavetta S, Patel S, Woerle HJ.
    J Diabetes Complications; 2013 Dec 14; 27(3):274-9. PubMed ID: 23403068
    [Abstract] [Full Text] [Related]

  • 14. Safety and tolerability of linagliptin in Asians with type 2 diabetes: a pooled analysis of 4457 patients from 21 randomized, double-blind, placebo-controlled clinical trials.
    Kanasaki K, Qu S, Yamamoto F, Schepers C, Sani Simões R, Yabe D, Ji L.
    Expert Opin Drug Saf; 2022 Mar 14; 21(3):425-434. PubMed ID: 34711126
    [Abstract] [Full Text] [Related]

  • 15. Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease.
    McGill JB, Yki-Järvinen H, Crowe S, Woerle HJ, von Eynatten M.
    Diab Vasc Dis Res; 2015 Jul 14; 12(4):249-57. PubMed ID: 25941160
    [Abstract] [Full Text] [Related]

  • 16. Efficacy and safety of linagliptin according to patient baseline characteristics: A pooled analysis of three phase 3 trials.
    Del Prato S, Patel S, Crowe S, von Eynatten M.
    Nutr Metab Cardiovasc Dis; 2016 Oct 14; 26(10):886-92. PubMed ID: 27484756
    [Abstract] [Full Text] [Related]

  • 17. Comparable pharmacodynamics, efficacy, and safety of linagliptin 5 mg among Japanese, Asian and white patients with type 2 diabetes.
    Sarashina A, Friedrich C, Crowe S, Patel S, Graefe-Mody U, Hayashi N, Horie Y.
    J Diabetes Investig; 2016 Sep 14; 7(5):744-50. PubMed ID: 27180969
    [Abstract] [Full Text] [Related]

  • 18. Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial.
    Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle HJ.
    Lancet; 2013 Oct 26; 382(9902):1413-23. PubMed ID: 23948125
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and Cardiovascular Safety of Linagliptin as an Add-On to Insulin in Type 2 Diabetes: A Pooled Comprehensive Post Hoc Analysis.
    Zinman B, Ahrén B, Neubacher D, Patel S, Woerle HJ, Johansen OE.
    Can J Diabetes; 2016 Feb 26; 40(1):50-7. PubMed ID: 26474870
    [Abstract] [Full Text] [Related]

  • 20. Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study.
    Bajaj M, Gilman R, Patel S, Kempthorne-Rawson J, Lewis-D'Agostino D, Woerle HJ.
    Diabet Med; 2014 Dec 26; 31(12):1505-14. PubMed ID: 24824197
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.